{
  "meta": {
    "title": "General_Principles_Of_Fat_And_Cholesterol_Metabolism",
    "url": "https://brainandscalpel.vercel.app/general-principles-of-fat-and-cholesterol-metabolism-de2d310c.html",
    "scrapedAt": "2025-11-30T14:11:19.299Z"
  },
  "questions": [
    {
      "text": "A patient with uncontrolled diabetes mellitus is admitted to the intensive care unit for the management of diabetic ketoacidosis (DKA). Which of the following ketone bodies accumulate in patients with DKA? &#160;",
      "choices": [
        {
          "id": 1,
          "text": "Acetone only &#160;"
        },
        {
          "id": 2,
          "text": "&#914;-hydroxybutyrate only &#160;"
        },
        {
          "id": 3,
          "text": "Acetoacetate only &#160;&#160;"
        },
        {
          "id": 4,
          "text": "Acetone and acetoacetate &#160;"
        },
        {
          "id": 5,
          "text": "Acetoacetate, acetone, and &#946;-hydroxybutyrate &#160;"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<strong>Three ketone bodies</strong> are produced and accumulate in diabetic ketoacidosis. Under metabolic conditions associated with a high rate of fatty acid oxidation, the liver produces considerable quantities of <strong>acetoacetate and &#946;-hydroxybutyrate</strong>. Acetoacetate continually undergoes spontaneous decarboxylation to yield <strong>acetone</strong>. These three substances are collectively known as the ketone bodies. &#160;<br><hr><h4 style='color: var(--accent-blue); margin-top:16px; margin-bottom:8px;'>Option Analysis</h4><div style='margin-bottom: 12px;'><strong>❌ Acetone only &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: This answer choice is incorrect. All three ketone bodies accumulate in patients with DKA. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ &#914;-hydroxybutyrate only &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: This answer choice is incorrect. All three ketone bodies accumulate in patients with DKA.</span></div><div style='margin-bottom: 12px;'><strong>❌ Acetoacetate only &#160;&#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: This answer choice is incorrect. All three ketone bodies accumulate in patients with DKA. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Acetone and acetoacetate &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: This answer choice is incorrect. All three ketone bodies accumulate in patients with DKA. &#160;</span></div><div style='margin-bottom: 12px;'><strong>✅ Acetoacetate, acetone, and &#946;-hydroxybutyrate &#160;:</strong><br><span style='opacity:0.9'><strong>Correct</strong>: See Main Explanation. &#160;</span></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "N/A",
      "difficulty": "N/A"
    },
    {
      "text": "A group of students are studying the metabolic sites of major cellular processes. Which of the following steps in fatty acid synthesis is crucial to transport acetyl-CoA from the mitochondria to the cytoplasm? &#160;",
      "choices": [
        {
          "id": 1,
          "text": "Carnitine shuttle &#160;&#160;"
        },
        {
          "id": 2,
          "text": "Citrate shuttle &#160;"
        },
        {
          "id": 3,
          "text": "Transamination reactions &#160;"
        },
        {
          "id": 4,
          "text": "Cori cycle &#160;"
        },
        {
          "id": 5,
          "text": "Cahill cycle &#160;"
        }
      ],
      "correct_choice_id": 2,
      "solution": "For fatty acid biosynthesis, acetyl-CoA has to be transported from the mitochondria to the cytoplasm. This is done via a shuttle system called the<strong>&#160;citrate shuttle</strong>. The citrate shuttle <strong>transports acetyl-CoA</strong> out of the mitochondria by combining it with <strong>oxaloacetate&#160;</strong>to form citrate. Once citrate is in the cytoplasm, it is converted back into acetyl-CoA and oxaloacetate, allowing acetyl-CoA to be used in fatty acid synthesis.<br><div><img src=\"https://d16qt3wv6xm098.cloudfront.net/AcgfkWvgTJ_UEdU1Y8WgoovLQVmOjD87/_.png\"></div><br><br><hr><h4 style='color: var(--accent-blue); margin-top:16px; margin-bottom:8px;'>Option Analysis</h4><div style='margin-bottom: 12px;'><strong>❌ Carnitine shuttle &#160;&#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: The carnitine shuttle represents a mechanism by which long-chain fatty acids are transported into the mitochondrial matrix for the purpose of &#946;-oxidation and energy production. It has no role in the transport of acetyl-CoA from the mitochondria to the cytoplasm in fatty acid synthesis. &#160;</span></div><div style='margin-bottom: 12px;'><strong>✅ Citrate shuttle &#160;:</strong><br><span style='opacity:0.9'><strong>Correct</strong>: See Main Explanation. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Transamination reactions &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Transamination reactions interconvert pairs of &#945;-amino acids and &#945;-keto acids and are catalyzed by aminotransferases. It has no role in the transport of acetyl-CoA from the mitochondria to the cytoplasm. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Cori cycle &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Cori cycle refers to the process of transporting lactate from cells that are undergoing anaerobic metabolism to the liver where it is used to provide glucose back to the cells. It has no role in the transport of acetyl-CoA from the mitochondria to the cytoplasm.</span></div><div style='margin-bottom: 12px;'><strong>❌ Cahill cycle &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Cahill cycle is one of the two mechanisms in humans which help in the transport of ammonia to the liver from tissues so that ammonia can be converted into urea. It has no role in the transport of acetyl-CoA from the mitochondria to the cytoplasm.</span></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "N/A",
      "difficulty": "N/A"
    },
    {
      "text": "A mountain climber in the Himalayas has been out of food and water for the last four days. Which of the following is the main source of energy for maintaining metabolic processes in the brain in this patient? &#160;",
      "choices": [
        {
          "id": 1,
          "text": "Glycolysis"
        },
        {
          "id": 2,
          "text": "Gluconeogenesis"
        },
        {
          "id": 3,
          "text": "Free fatty acids &#160;"
        },
        {
          "id": 4,
          "text": "Ketone bodies &#160;&#160;"
        },
        {
          "id": 5,
          "text": "Glycogenesis"
        }
      ],
      "correct_choice_id": 4,
      "solution": "In the state of starvation, after three days,<strong> ketone bodies</strong> become the main source of energy for the brain. Ketone bodies are a group of carbon-containing molecules produced by liver mitochondria using a 2-carbon molecule called acetyl-CoA. The liver makes ketone bodies in physiologic states like <strong>prolonged fasting or exercise</strong> as well as in pathological states like <strong>type 1 diabetes mellitus or alcoholism</strong>. Ketone bodies can be released into the circulation and get picked up by the majority of cells. Inside the cells, they are reconverted back into acetyl-CoA, at which point they can then enter the mitochondria and produce ATP. &#160;<br><hr><h4 style='color: var(--accent-blue); margin-top:16px; margin-bottom:8px;'>Option Analysis</h4><div style='margin-bottom: 12px;'><strong>❌ Glycolysis:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Glycolysis and aerobic respiration are the main sources of energy in fed state. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Gluconeogenesis:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Hepatic gluconeogenesis from peripheral tissue lactate and alanine and from adipose tissue glycerol and propionyl- CoA provides energy between 1-3 days of starvation. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Free fatty acids &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Adipocytes release free fatty acids (FFA) between 1-3 days of starvation&#8211;skeletal myocytes and hepatocytes can shift fuel use from glucose to FFA between 1-3 days of starvation.</span></div><div style='margin-bottom: 12px;'><strong>✅ Ketone bodies &#160;&#160;:</strong><br><span style='opacity:0.9'><strong>Correct</strong>: See Main Explanation. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Glycogenesis:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Hepatic glycogenolysis is the major source of energy during fasting state between meals. Glycogen reserves depleted after day one of starvation. &#160;</span></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "N/A",
      "difficulty": "N/A"
    },
    {
      "text": "A study is done on the processes of fat digestion and absorption in order to develop novel pharmacologics that can help prevent diseases associated with increased levels of fat and lipids in the blood. Which of the following is true regarding the digestion and absorption of fats and lipids? &#160;",
      "choices": [
        {
          "id": 1,
          "text": "Absorbed fat and lipids get transported from enterocytes through lymphatic ducts &#160;"
        },
        {
          "id": 2,
          "text": "Lipase is the enzyme that breaks down fat globules and is only produced by the pancreas &#160;"
        },
        {
          "id": 3,
          "text": "Free fatty acids and monoglycerides from digested fat get absorbed into the enterocytes and then directly into the blood &#160;&#160;"
        },
        {
          "id": 4,
          "text": "The process of fat digestion and absorption ends in the duodenum &#160;"
        },
        {
          "id": 5,
          "text": "Digested fats get absorbed into enterocytes as triglycerides &#160;"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<strong>Fats&#160;</strong>and <strong>lipids&#160;</strong>are essential components of the human diet, and the process of digestion and absorption of fats and lipids is a complex process that starts in the mouth. &#160; <br><br>The enzyme <strong>lipase&#160;</strong>is the major enzyme responsible for breaking down fats. It is secreted firstly in the saliva and starts the process of breaking down fat while in the mouth, which continues in the stomach too. However, the majority of the process of fat digestion and absorption takes place in the <strong>small intestines. &#160;&#160;</strong><br><br>When fat globules reach the duodenum, <strong>pancreatic secretions&#160;</strong>containing lipase start breaking down fat globules. This process is facilitated by <strong>bile salts</strong>, which <strong>increases the surface area of fat globules</strong> for lipase to work. Lipase breaks down fat globules into free fatty acids and monoglycerides, which are then absorbed by the enterocytes.<div><img src=\"https://d16qt3wv6xm098.cloudfront.net/zROneEriRkGfcfnVWKR6mrMiT4OYizfb/_.png\"></div><br><br><br>Once in the enterocytes, free fatty acids and monoglycerides join again into triglycerides, which are assembled into <strong>chylomicrons</strong>. Finally, chylomicrons exit the enterocytes into the<strong>&#160;lymphatic capillaries</strong>, until it reaches the thoracic duct, and finally enter the bloodstream. &#160;<br><div><img src=\"https://d16qt3wv6xm098.cloudfront.net/rTYss76HSGS4WE_Qs8ABXhKUQiajXciA/_.png\"></div><br><br><hr><h4 style='color: var(--accent-blue); margin-top:16px; margin-bottom:8px;'>Option Analysis</h4><div style='margin-bottom: 12px;'><strong>✅ Absorbed fat and lipids get transported from enterocytes through lymphatic ducts &#160;:</strong><br><span style='opacity:0.9'><strong>Correct</strong>: See Main Explanation. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Lipase is the enzyme that breaks down fat globules and is only produced by the pancreas &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Lipase is found in lingual secretions, stomach secretions, and pancreatic secretions. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Free fatty acids and monoglycerides from digested fat get absorbed into the enterocytes and then directly into the blood &#160;&#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Free fatty acids and monoglycerides, once absorbed into the enterocytes, assemble again into triglycerides which are carried by chylomicrons into the lymphatic system. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ The process of fat digestion and absorption ends in the duodenum &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: The process of fat digestion and absorption continues through the small bowel into the jejunum. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Digested fats get absorbed into enterocytes as triglycerides &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Fat and lipid digestion yields monoglycerides and free fatty acids, which are absorbed into the enterocytes. Within the enterocytes, monoglycerides and fatty acids assemble again into triglycerides. &#160;</span></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "N/A",
      "difficulty": "N/A"
    },
    {
      "text": "Biochemistry researchers are studying the pathway of fatty acid synthesis with students in the laboratory. Which of the following is the rate-limiting step of fatty acid synthesis? &#160;",
      "choices": [
        {
          "id": 1,
          "text": "Fatty acyl-CoA &#8594; long-chain acylcarnitine &#160;"
        },
        {
          "id": 2,
          "text": "Acetyl-CoA &#160;&#8594; Malonyl-CoA"
        },
        {
          "id": 3,
          "text": "Phosphoenolpyruvate &#8594; pyruvate &#160;"
        },
        {
          "id": 4,
          "text": "Oxaloacetate &#8594; phosphoenolpyruvate &#160;"
        },
        {
          "id": 5,
          "text": "Pyruvate &#160;&#8594; &#160;oxaloacetate &#160;"
        }
      ],
      "correct_choice_id": 2,
      "solution": "&#160;Fatty acid synthesis is the creation of fatty acids from acetyl-CoA and NADPH. The rate-limiting step is the conversion of <strong>malonyl-CoA to acetyl-CoA</strong> which is catalyzed by <strong>acetyl-CoA carboxylase</strong>. This enzyme is regulated by the following factors: &#160;<br>- Activators: Insulin and citrate &#160;<br>- Inhibitors: Glucagon and palmitoyl-CoA &#160;<br><div><img src=\"https://d16qt3wv6xm098.cloudfront.net/7flFjSsmRoSQQLVvAQQv15bzT__cq2pF/_.png\"></div><br><br><hr><h4 style='color: var(--accent-blue); margin-top:16px; margin-bottom:8px;'>Option Analysis</h4><div style='margin-bottom: 12px;'><strong>❌ Fatty acyl-CoA &#8594; long-chain acylcarnitine &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: This answer choice is the rate-limiting step of beta-oxidation of fatty acid. &#160;</span></div><div style='margin-bottom: 12px;'><strong>✅ Acetyl-CoA &#160;&#8594; Malonyl-CoA:</strong><br><span style='opacity:0.9'><strong>Correct</strong>: See Main Explanation. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Phosphoenolpyruvate &#8594; pyruvate &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: This answer choice is the last step of the glycolytic pathway catalyzed by pyruvate kinase. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Oxaloacetate &#8594; phosphoenolpyruvate &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: This is an irreversible step in gluconeogenesis and is catalyzed by phosphoenolpyruvate carboxykinase.</span></div><div style='margin-bottom: 12px;'><strong>❌ Pyruvate &#160;&#8594; &#160;oxaloacetate &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: This step is catalyzed by pyruvate carboxylase in gluconeogenesis. &#160;</span></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "N/A",
      "difficulty": "N/A"
    },
    {
      "text": "A group of students are studying the metabolic sites of major cellular processes. Which of the following best describes the cellular location of the fatty acid oxidation in the cell? &#160;",
      "choices": [
        {
          "id": 1,
          "text": "Mitochondria only &#160;"
        },
        {
          "id": 2,
          "text": "Cytoplasm only &#160;&#160;"
        },
        {
          "id": 3,
          "text": "Mitochondria, cytoplasm and endoplasmic reticulum &#160;"
        },
        {
          "id": 4,
          "text": "Nucleolus only &#160;"
        },
        {
          "id": 5,
          "text": "Cytoplasm and nucleus &#160;"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<strong>Fatty acid &#946;-oxidation</strong> is a multistep process by which fatty acids are broken down by various tissues to produce energy. It primarily takes place in the <strong>mitochondria </strong>of the heart, skeletal muscle, and liver cells. &#160;<br><hr><h4 style='color: var(--accent-blue); margin-top:16px; margin-bottom:8px;'>Option Analysis</h4><div style='margin-bottom: 12px;'><strong>✅ Mitochondria only &#160;:</strong><br><span style='opacity:0.9'><strong>Correct</strong>: See Main Explanation. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Cytoplasm only &#160;&#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Metabolic processes that occur in cytoplasm include glycolysis, HMP shunt, and synthesis of cholesterol (SER), proteins (ribosomes, RER), fatty acids, and nucleotides. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Mitochondria, cytoplasm and endoplasmic reticulum &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Gluconeogenesis takes place in the cytoplasm, mitochondria, and endoplasmic reticulum. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Nucleolus only &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Fatty acid oxidation occurs in the mitochondria.</span></div><div style='margin-bottom: 12px;'><strong>❌ Cytoplasm and nucleus &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Fatty acid oxidation occurs in the mitochondria. &#160;</span></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "N/A",
      "difficulty": "N/A"
    },
    {
      "text": "A group of students are studying the metabolic sites of major cellular processes. Which of the following best describes the mechanism by which long-chain fatty acids are transported into the mitochondrial matrix for the purpose of &#946;-oxidation and energy production?",
      "choices": [
        {
          "id": 1,
          "text": "Carnitine shuttle &#160;"
        },
        {
          "id": 2,
          "text": "Citrate shuttle &#160;"
        },
        {
          "id": 3,
          "text": "Transamination reactions &#160;"
        },
        {
          "id": 4,
          "text": "Cori cycle &#160;"
        },
        {
          "id": 5,
          "text": "Cahill cycle &#160;"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<strong>Fatty acid &#946;-oxidation</strong> is a multistep process by which fatty acids are broken down by various tissues to produce energy. Once the fatty acid is inside the cell, a cytosolic enzyme called fatty acyl-CoA synthetase adds a coenzyme A molecule to the end of the fatty acid, turning it into a metabolically active fatty acyl-CoA. The mitochondria is composed of two membranes&#8211;an outer membrane and an inner membrane&#8211;with a small space in between and the mitochondrial matrix at the core. The enzymes required for beta-oxidation are located in the mitochondrial matrix; however, the fatty acid cannot cross the inner mitochondrial membrane when CoA is attached to it. Therefore, an enzyme within the outer mitochondrial membrane called<strong> carnitine acyltransferase 1 (CAT1)</strong>, replaces the CoA with carnitine, making fatty acyl-carnitine and a free CoA, both of which can easily cross the inner mitochondrial membrane. Then, along the inner mitochondrial membrane, another enzyme called <strong>carnitine acyltransferase 2 (CAT2)</strong>, substitutes carnitine and CoA back; therefore, regenerating fatty acyl-CoA and free carnitine&#8211;which is now within the mitochondrial matrix. This whole process is called the <strong>carnitine shuttle</strong>. &#160;<br><div><img src=\"https://d16qt3wv6xm098.cloudfront.net/F73o3g16QQetgy_-TJFnrVW6RdWxA8Ix/_.png\"></div><br><br><hr><h4 style='color: var(--accent-blue); margin-top:16px; margin-bottom:8px;'>Option Analysis</h4><div style='margin-bottom: 12px;'><strong>✅ Carnitine shuttle &#160;:</strong><br><span style='opacity:0.9'><strong>Correct</strong>: See Main Explanation.</span></div><div style='margin-bottom: 12px;'><strong>❌ Citrate shuttle &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: &#160;The citrate shuttle transports acetyl-CoA from the mitochondria to the cytoplasm, allowing acetyl-CoA to be used in fatty acid synthesis. &#160;It has no role in fatty acid oxidation. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Transamination reactions &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Transamination reactions interconvert pairs of &#945;-amino acids and &#945;-keto acids and are catalyzed by aminotransferases. It has no role in fatty acid oxidation. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Cori cycle &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Cori cycle refers to the process of transporting lactate from cells that are undergoing anaerobic metabolism to the liver where it is used to provide glucose back to the cells. It has no role in fatty acid oxidation. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Cahill cycle &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Cahill cycle is one of the two mechanisms in humans which help in the transport of ammonia to the liver from tissues so that ammonia can be converted into urea. It has no role in fatty acid oxidation. &#160;</span></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "N/A",
      "difficulty": "N/A"
    },
    {
      "text": "A patient with uncontrolled diabetes mellitus is admitted to the intensive care unit for the management of diabetic ketoacidosis. One of the medical students notices that the patient's breath smells sweet, similar to the odor of fruits. Which of the following ketone bodies is responsible for this odor? &#160;",
      "choices": [
        {
          "id": 1,
          "text": "Acetone only &#160;"
        },
        {
          "id": 2,
          "text": "&#946;-hydroxybutyrate only &#160;"
        },
        {
          "id": 3,
          "text": "Acetoacetate only &#160;"
        },
        {
          "id": 4,
          "text": "Acetone and acetoacetate &#160;"
        },
        {
          "id": 5,
          "text": "Acetoacetate, acetone, and &#946;-hydroxybutyrate &#160;"
        }
      ],
      "correct_choice_id": 1,
      "solution": "During ketone body metabolism, the extrahepatic tissues utilize acetoacetate and &#946;-hydroxybutyrate (3-hydroxybutyrate) as respiratory substrates. Acetone is a waste product which, as it is volatile, can be excreted via the lungs. That is why in pathological states like diabetic ketoacidosis, the patient&#8217;s breath can smell like fruit&#8212;this is actually the <strong>scent of acetone. &#160;</strong><br><hr><h4 style='color: var(--accent-blue); margin-top:16px; margin-bottom:8px;'>Option Analysis</h4><div style='margin-bottom: 12px;'><strong>✅ Acetone only &#160;:</strong><br><span style='opacity:0.9'><strong>Correct</strong>: See Main Explanation. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ &#946;-hydroxybutyrate only &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: This answer choice is incorrect. Although acetone is exhaled by the lungs, &#946;-hydroxybutyrate is not. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Acetoacetate only &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: This answer choice is incorrect. Acetoacetate is not exhaled by lungs. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Acetone and acetoacetate &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: This answer choice is incorrect. Although acetone is exhaled by the lungs, acetoacetate is not. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Acetoacetate, acetone, and &#946;-hydroxybutyrate &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: This answer choice is incorrect. Although acetone is exhaled by the lungs, acetoacetate and &#946;-hydroxybutyrate are not. &#160;</span></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "N/A",
      "difficulty": "N/A"
    },
    {
      "text": "Ketogenesis is the biochemical process through which organisms produce ketone bodies by breaking down fatty acids and ketogenic amino acids. Which of the following organs/cells utilize ketone bodies for energy? &#160;",
      "choices": [
        {
          "id": 1,
          "text": "Red blood cells &#160;&#160;"
        },
        {
          "id": 2,
          "text": "Hepatocytes"
        },
        {
          "id": 3,
          "text": "Neurons"
        },
        {
          "id": 4,
          "text": "Renal tubular cells &#160;"
        },
        {
          "id": 5,
          "text": "Adrenal epithelial cells &#160;"
        }
      ],
      "correct_choice_id": 3,
      "solution": "Ketone bodies can be utilized as fuel in the<strong> heart, brain, and muscle</strong> but not the liver. Once formed, the ketone bodies are transported from the liver to other tissues where acetoacetate and &#946;-hydroxybutyrate can be reconverted to acetyl-CoA to produce reducing equivalents (NADH and FADH2) via the citric acid cycle. Though it is the source of ketone bodies, the liver cannot use them for energy because it lacks the enzyme thiophorase (&#946;-ketoacyl-CoA transferase). &#160;&#160;<br><hr><h4 style='color: var(--accent-blue); margin-top:16px; margin-bottom:8px;'>Option Analysis</h4><div style='margin-bottom: 12px;'><strong>❌ Red blood cells &#160;&#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Red blood cells cannot utilize ketones; they strictly use glucose. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Hepatocytes:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Although hepatocytes are the source of ketone bodies, the liver cannot use them for energy because it lacks the enzyme thiophorase (&#946;-ketoacyl-CoA transferase). &#160;</span></div><div style='margin-bottom: 12px;'><strong>✅ Neurons:</strong><br><span style='opacity:0.9'><strong>Correct</strong>: See Main Explanation. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Renal tubular cells &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Ketone bodies are filtered and reabsorbed in the kidney. It is not utilized by the kidney for energy. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Adrenal epithelial cells &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Adrenal epithelial cells do not utilize ketone bodies. &#160;</span></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "N/A",
      "difficulty": "N/A"
    },
    {
      "text": "Biochemistry researchers are studying the pathway of fatty acid oxidation with students in the laboratory. Which of the following is the rate-limiting step of fatty acid oxidation? &#160;",
      "choices": [
        {
          "id": 1,
          "text": "Fatty acyl-CoA &#8594; long-chain acylcarnitine &#160;"
        },
        {
          "id": 2,
          "text": "Malonyl CoA &#160;&#8594; acetyl-CoA &#160;"
        },
        {
          "id": 3,
          "text": "Phosphoenolpyruvate &#8594; pyruvate &#160;"
        },
        {
          "id": 4,
          "text": "Oxaloacetate &#8594; phosphoenolpyruvate &#160;"
        },
        {
          "id": 5,
          "text": "Pyruvate &#160;&#8594; &#160;oxaloacetate &#160;"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<strong>Fatty acid &#946;-oxidation</strong> is a multistep process by which fatty acids are broken down by various tissues to produce energy. Fatty acids primarily enter a cell via fatty acid protein transporters on the cell surface. &#160;Once inside the cell, a -CoA group is added to the fatty acid by fatty acyl-CoA synthase, forming long-chain acyl-CoA. <strong>C</strong><strong>arnitine palmitoyltransferase 1</strong> converts the long-chain acyl-CoA to long-chain acylcarnitine and allows the fatty acid moiety to be transported across the inner mitochondrial membrane via carnitine translocase (CAT), which exchanges long-chain acylcarnitines for carnitine. This is also the rate-limiting step in fatty acid &#946;-oxidation. This step is <strong>inhibited by malonyl-CoA. &#160;</strong><br><hr><h4 style='color: var(--accent-blue); margin-top:16px; margin-bottom:8px;'>Option Analysis</h4><div style='margin-bottom: 12px;'><strong>✅ Fatty acyl-CoA &#8594; long-chain acylcarnitine &#160;:</strong><br><span style='opacity:0.9'><strong>Correct</strong>: See Main Explanation. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Malonyl CoA &#160;&#8594; acetyl-CoA &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: This answer choice is the rate-limiting step of fatty acid synthesis. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Phosphoenolpyruvate &#8594; pyruvate &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: This answer choice is the last step of the glycolytic pathway catalyzed by pyruvate kinase. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Oxaloacetate &#8594; phosphoenolpyruvate &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: &#160;This is irreversible in gluconeogenesis and is catalyzed by phosphoenolpyruvate carboxykinase.</span></div><div style='margin-bottom: 12px;'><strong>❌ Pyruvate &#160;&#8594; &#160;oxaloacetate &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: This step is catalyzed by pyruvate carboxylase in gluconeogenesis. &#160;</span></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "N/A",
      "difficulty": "N/A"
    },
    {
      "text": "A group of students are studying the metabolic sites of major cellular processes. Which of the following best describes the cellular location of ketone bodies synthesis in the cell? &#160;",
      "choices": [
        {
          "id": 1,
          "text": "Mitochondria only &#160;"
        },
        {
          "id": 2,
          "text": "Cytoplasm only &#160;"
        },
        {
          "id": 3,
          "text": "Mitochondria, cytoplasm, and endoplasmic reticulum &#160;"
        },
        {
          "id": 4,
          "text": "Nucleolus only &#160;"
        },
        {
          "id": 5,
          "text": "Cytoplasm and nucleus &#160;"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<strong>Ketone bodies</strong> (e.g., acetoacetate, 3-hydroxybutyrate, and acetone) are formed in <strong>hepatic </strong>mitochondria when there is a high rate of fatty acid oxidation. The pathway of ketogenesis involves synthesis and breakdown of HMG-CoA by two key enzymes: HMG-CoA synthase and HMG-CoA lyase. &#160;<br><hr><h4 style='color: var(--accent-blue); margin-top:16px; margin-bottom:8px;'>Option Analysis</h4><div style='margin-bottom: 12px;'><strong>✅ Mitochondria only &#160;:</strong><br><span style='opacity:0.9'><strong>Correct</strong>: See Main Explanation. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Cytoplasm only &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Glycolysis; HMP shunt; and synthesis of cholesterol (SER), proteins (ribosomes, RER), fatty acids, and nucleotides occur in the cytoplasm. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Mitochondria, cytoplasm, and endoplasmic reticulum &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Gluconeogenesis takes place in the cytoplasm, mitochondria, and endoplasmic reticulum. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Nucleolus only &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Ketogenesis occurs in the mitochondria of hepatocytes. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Cytoplasm and nucleus &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: &#160;Ketogenesis occurs in the mitochondria of hepatocytes.</span></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "N/A",
      "difficulty": "N/A"
    },
    {
      "text": "A group of students are studying the metabolic sites of major cellular processes. Which of the following best describes the cellular location of fatty acid synthesis in the cell? &#160;",
      "choices": [
        {
          "id": 1,
          "text": "Mitochondria only &#160;"
        },
        {
          "id": 2,
          "text": "Cytoplasm only &#160;"
        },
        {
          "id": 3,
          "text": "Mitochondria, cytoplasm, and endoplasmic reticulum &#160;"
        },
        {
          "id": 4,
          "text": "Nucleolus only &#160;"
        },
        {
          "id": 5,
          "text": "Cytoplasm and nucleus &#160;"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<strong>Fatty acid</strong> <strong>synthesis </strong>is the creation of fatty acids from acetyl-CoA and NADPH. This process takes place in the <strong>cytoplasm </strong>of the cell. It predominantly occurs in the liver, lactating mammary glands, and adipose tissue. &#160;<br><hr><h4 style='color: var(--accent-blue); margin-top:16px; margin-bottom:8px;'>Option Analysis</h4><div style='margin-bottom: 12px;'><strong>❌ Mitochondria only &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Reactions that occur solely in the mitochondria include fatty acid oxidation (&#946;-oxidation), acetyl-CoA production, TCA cycle, oxidative phosphorylation, and ketogenesis. &#160;</span></div><div style='margin-bottom: 12px;'><strong>✅ Cytoplasm only &#160;:</strong><br><span style='opacity:0.9'><strong>Correct</strong>: See Main Explanation. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Mitochondria, cytoplasm, and endoplasmic reticulum &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Gluconeogenesis takes place in the cytoplasm, mitochondria, and endoplasmic reticulum. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Nucleolus only &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Fatty acid synthesis occurs in the cytoplasm. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Cytoplasm and nucleus &#160;:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Fatty acid synthesis occurs in the cytoplasm. &#160;</span></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "N/A",
      "difficulty": "N/A"
    },
    {
      "text": "A 46-year-old man presents to the office for the evaluation of abnormal lipid profile. He does not have any active complaints at this visit. Past medical history is significant for hypertension and dyslipidemia. Current medication includes lisinopril. Approximately 6 months ago, he was started on a low-fat diet to help him lose weight and improve dyslipidemia. Family history is significant for type II diabetes mellitus and myocardial infarction in his father. Temperature is 37.0&#176;C (98.6&#176;F), pulse is 70/min, respirations are 16/min, and blood pressure is 130/85 mmHg. Physical examination is unremarkable. A repeat lipid panel obtained last week reveals low-density lipoprotein (LDL) levels of 250 mg/dL. Chart review reveals the patient was unable to tolerate statin therapy in the past due to myopathy. The physician recommends the initiation of ezetimibe. Which of the following best describes the most likely mechanism of action of ezetimibe? &#160;",
      "choices": [
        {
          "id": 1,
          "text": "Inhibition of lipolysis in adipose tissue"
        },
        {
          "id": 2,
          "text": "Inhibition of hydroxymethylglutaryl (HMG) CoA reductase"
        },
        {
          "id": 3,
          "text": "Inhibition of intestinal bile acid reabsorption"
        },
        {
          "id": 4,
          "text": "Inhibition of intestinal cholesterol absorption"
        },
        {
          "id": 5,
          "text": "Inhibition of low-density-lipoprotein receptor (LDL-R) degradation"
        }
      ],
      "correct_choice_id": 4,
      "solution": "This patient with <strong>elevated LDL</strong> cholesterol levels, not improved by dietary changes, is started on <strong>ezetimibe</strong>, a lipid lowering drug. It <strong>prevents cholesterol absorption</strong> at the intestinal brush border by <strong>inhibiting Niemann-Pick C1 like 1 (NPC1L1) protein</strong>, which is a critical mediator of cholesterol absorption. This results in a <strong>significant reduction in LDL-cholesterol levels</strong>. However, little to no effect is observed on very-low-density lipoproteins (VLDL) or high-density lipoproteins (HDL) levels. It is usually indicated in patients with <strong>hyperlipidemia </strong>in combination with statins or as a monotherapy to prevent the side effects of high dose statins (e.g., myopathy, deranged liver aminotransferase). Moreover, it can also be combined with fenofibrate to treat mixed hyperlipidemia. Side effects of ezetimibe<strong> include gastrointestinal (GI) upset, headache</strong> and, rarely, liver damage or myalgias. &#160;<br><hr><h4 style='color: var(--accent-blue); margin-top:16px; margin-bottom:8px;'>Option Analysis</h4><div style='margin-bottom: 12px;'><strong>❌ Inhibition of lipolysis in adipose tissue:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Niacin, a lipid lowering drug, acts to prevent lipolysis by inhibiting hormone-sensitive lipase in adipose tissue. Its overall effect is a major increase in HDL and a decrease in LDL. Ezetimibe has no direct effect on lipolysis in adipose tissue. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Inhibition of hydroxymethylglutaryl (HMG) CoA reductase:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Statins are lipid-lowering drugs that competitively inhibit HMG CoA reductase, an enzyme which normally converts HMG CoA to mevalonate. This leads to a decrease in hepatic cholesterol synthesis and increase in LDL recycling. Although ezetimibe helps reduce LDL levels, it does not directly affect HMG CoA reductase. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Inhibition of intestinal bile acid reabsorption:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Bile acid resins (e.g., cholestyramine, colestipol) are lipid lowering drugs that act by binding the bile acids (not cholesterol) in the intestine to prevent its reabsorption at the intestinal brush border. &#160;</span></div><div style='margin-bottom: 12px;'><strong>✅ Inhibition of intestinal cholesterol absorption:</strong><br><span style='opacity:0.9'><strong>Correct</strong>: See Main Explanation. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Inhibition of low-density-lipoprotein receptor (LDL-R) degradation:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: PCSK9 inhibitors act by inhibiting the degradation of LDL-R, facilitating the removal of LDL from the bloodstream. Alirocumab is a common example of this drug. &#160;</span></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "N/A",
      "difficulty": "N/A"
    },
    {
      "text": "A 45-year-old man comes to the office for the evaluation of his abnormal lipid panel and is currently asymptomatic. Past medical history is significant for type II diabetes mellitus, and an episode of pancreatitis 6 months ago. Current medications include metformin and atorvastatin. Family history is significant for myocardial infarction in father and chronic renal failure in mother. He smokes a pack of cigarettes daily, drinks 2 glasses of beer on weekends and does not use illicit drugs. Vitals are within normal limits. His BMI is 33.5 kg/m<sup>2</sup>. Physical examination is noncontributory. Fasting laboratory workup at today&#8217;s visit is shown below. The patient is recommended to maintain a low-fat diet to reduce weight, and fenofibrate is added to his medication regime. Which of the following best describes the effect of fenofibrate therapy on serum LDL, HDL and TGs? &#160;<br><br><table><tbody><tr><td><strong>Laboratory value</strong><br></td><td><strong>Results</strong><br></td></tr><tr><td>Glucose<br></td><td>120 mg/dL<br></td></tr><tr><td>Low-density lipoprotein (LDL) &#160; <br></td><td>160 mg/dL<br></td></tr><tr><td>High-density lipoprotein (HDL)<br></td><td>30 mg/dL<br></td></tr><tr><td>Triglycerides<br></td><td>700 mg/dL<br></td></tr><tr><td>Hemoglobin A1c<br></td><td>6.6 %<br></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br>",
      "choices": [
        {
          "id": 1,
          "text": ""
        },
        {
          "id": 2,
          "text": ""
        },
        {
          "id": 3,
          "text": ""
        },
        {
          "id": 4,
          "text": ""
        },
        {
          "id": 5,
          "text": ""
        }
      ],
      "correct_choice_id": 4,
      "solution": "This patient with moderate-to-severe <strong>hypertriglyceridemia </strong>(TG &gt;500 mg/dL) and a past medical history of an episode of pancreatitis is likely to benefit from fibrate therapy.<br><br>Fibrates activate <strong>peroxisome proliferator-activated receptor alpha (PPAR&#945;)</strong> which is a major regulator of lipid metabolism. PPAR&#945; decreases the liver's very-low-density lipoprotein (VLDL) levels and <strong>increases the activity of lipoprotein lipase (LPL)</strong> in the adipose tissues. LPL in turn <strong>hydrolyzes </strong>the <strong>triglycerides </strong>in chylomicron and VLDL to <strong>free fatty acids (FFA)</strong>, thus lowering triglyceride levels. The FFA can be used for energy or converted back to TGs. Finally fibrates also increase the synthesis of HDL by facilitating the transfer of TGs from chylomicrons and VLDL to HDL. Unlike statins, fibrates have little effect on LDL, whereas, statins are not as effective in lowering TGs. Therefore, both can be combined to treat <strong>mixed dyslipidemia</strong>. &#160;<br><hr><h4 style='color: var(--accent-blue); margin-top:16px; margin-bottom:8px;'>Option Analysis</h4><div style='margin-bottom: 12px;'><strong>❌ :</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Statins inhibit the action of hydroxymethylglutaryl (HMG) CoA reductase, which normally converts HMG CoA to mevalonate. This leads to a decrease in hepatic cholesterol synthesis and increase in low density lipoproteins (LDL) recycling by the up-regulation of LDL receptors on hepatic cells. It has a moderate effect on TG levels. &#160;&#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ :</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Bile acid resins (e.g. cholestyramine) tend to decrease LDL cholesterol by preventing bile acid reabsorption in the intestine (enterohepatic circulation). It slightly increases the levels of TGs rather than decreasing it. &#160;&#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ :</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: These changes are observed with fish oil and marine omega-3 fatty acids. It decreases the transport of free fatty acids to the liver and inhibits the activity of TG-synthesizing enzymes. It decreases TGs only at high doses. &#160;&#160;</span></div><div style='margin-bottom: 12px;'><strong>✅ :</strong><br><span style='opacity:0.9'><strong>Correct</strong>: See Main Explanation. &#160;&#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ :</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: A significant increase in HDL is observed with the use of niacin. A major decrease in TG is not seen. &#160;&#160;</span></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "N/A",
      "difficulty": "N/A"
    },
    {
      "text": "A 46-year-old woman presents to the office for evaluation of an abnormal lipid profile, which was discovered during routine testing. She has no acute symptoms but has had difficulty following a low carbohydrate diet that her previous physician recommended. Past medical history is significant for hypertension and type II diabetes mellitus. Current medications include metformin, lisinopril, and atorvastatin. Family history is significant for type II diabetes mellitus and myocardial infarction in the patient&#8217;s father. Temperature is 37.0&#176;C (98.6&#176;F), pulse is 80/min, respirations are 20/min, and blood pressure is 135/85 mmHg. Body mass index is 34 kg/m<sup>2</sup>. Physical examination is unremarkable. Laboratory results are shown below. The patient is encouraged to exercise regularly and make dietary modifications. In addition, she is started on a medication to help control her triglyceride level. Which of the following enzymes is most likely affected by this drug? &#160;<br><br><table><tbody><tr><td><strong>Laboratory Value</strong><br></td><td><strong>Results</strong><br></td></tr><tr><td>Glucose<br></td><td>120 mg/dL &#160; <br></td></tr><tr><td>Low-density lipoprotein (LDL) &#160; <br></td><td>140 mg/dL &#160; <br></td></tr><tr><td>High-density lipoprotein (HDL) &#160; <br></td><td>30 mg/dL &#160; <br></td></tr><tr><td>Triglycerides (TGs) &#160; <br></td><td>900 mg/dL &#160; <br></td></tr><tr><td>Hemoglobin A1c &#160; <br></td><td>6.6% &#160; <br></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br>",
      "choices": [
        {
          "id": 1,
          "text": "Hydroxymethylglutaryl (HMG) CoA reductase"
        },
        {
          "id": 2,
          "text": "Lipoprotein lipase"
        },
        {
          "id": 3,
          "text": "Monoamine oxidase"
        },
        {
          "id": 4,
          "text": "Hormone-sensitive lipase"
        },
        {
          "id": 5,
          "text": "Phosphodiesterase-3"
        }
      ],
      "correct_choice_id": 2,
      "solution": "This patient has a significantly elevated <strong>triglyceride </strong>(TG) level (&gt; 500 mg/dL) and should be started on <strong>fibrate </strong>therapy along with lifestyle modifications.<br><br>Fibrates (e.g., fenofibrate, gemfibrozil, bezafibrate) activate <strong>peroxisome proliferator-activated receptor alpha</strong> (PPAR&#945;), which is a major regulator of lipid metabolism. PPAR&#945; <strong>decreases very-low-density lipoprotein</strong> (VLDL) <strong>synthesis </strong>and <strong>increases lipoprotein lipase </strong>(LPL) <strong>activity </strong>in adipose tissues. LPL, in turn, hydrolyzes the TGs in chylomicrons and VLDLs to <strong>free fatty acids</strong> (FFA), thus lowering triglyceride levels. Moreover, fibrates i<strong>ncrease the synthesis of HDLs</strong>, facilitating the transfer of TGs from chylomicrons and VLDL to HDL.<br><br>Fibrates are typically indicated when <strong>TG levels exceed 500 mg/dL</strong> and can potentially reduce the patient&#8217;s risk of developing pancreatitis. Although there is an increased risk of myopathy with the combined use of statin and fibrates, a combination of atorvastatin-fenofibrate is least likely to cause this adverse effect. &#160;<br><hr><h4 style='color: var(--accent-blue); margin-top:16px; margin-bottom:8px;'>Option Analysis</h4><div style='margin-bottom: 12px;'><strong>❌ Hydroxymethylglutaryl (HMG) CoA reductase:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Statins act to inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. This patient is already on a statin, which plays a major role in LDL reduction. In contrast, a fibrate would be more effective in managing the patient&#8217;s elevated triglyceride level. &#160;</span></div><div style='margin-bottom: 12px;'><strong>✅ Lipoprotein lipase:</strong><br><span style='opacity:0.9'><strong>Correct</strong>: See Main Explanation. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Monoamine oxidase:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Monoamine oxidase inhibitors (e.g. phenelzine) act to remove neurotransmitters norepinephrine, serotonin, and dopamine from the brain. They can be used in the treatment of major depressive disorder. Monoamine oxidase inhibitors have no proven efficacy against hypertriglyceridemia. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Hormone-sensitive lipase:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Niacin, a lipid-lowering drug, acts to prevent lipolysis by inhibiting hormone-sensitive lipase in adipose tissue. Its overall effect is a major increase in HDL and a decrease in LDL. It is not routinely used for the treatment of hypertriglyceridemia. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Phosphodiesterase-3:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Phosphodiesterase-3 inhibitors (e.g. milrinone) prevent the inactivation of intracellular second messengers (e.g., cyclic adenosine monophosphate, cyclic guanosine monophosphate). These medications are useful in the management of heart failure and intermittent claudication. However, they would not help in treating this patient&#8217;s hypertriglyceridemia. &#160;</span></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "N/A",
      "difficulty": "N/A"
    },
    {
      "text": "A 45-year-old woman presents to the office for her routine follow-up. She has no active complaints at this visit. Past medical history is significant for hypertension. Current medication includes lisinopril. Family history is significant for type II diabetes mellitus in her mother and myocardial infarction in her father. She drinks 2-3 beers on the weekends and does not smoke or use illicit drugs. Temperature is 37.0&#176;C (98.6&#176;F), pulse is 70/min, respirations are 16/min, and blood pressure is 130/85 mmHg. Physical examination is unremarkable. Her recent fasting lipid profile revealed an elevated low-density lipoprotein (LDL) and decreased high-density lipoprotein (HDL). The physician prescribes a lipid-lowering drug that prevents lipolysis by inhibiting hormone-sensitive lipase in adipose tissue. Which of the following is a potential adverse effect of this drug? &#160;",
      "choices": [
        {
          "id": 1,
          "text": "Myopathy"
        },
        {
          "id": 2,
          "text": "Hyperuricemia"
        },
        {
          "id": 3,
          "text": "Gallstones"
        },
        {
          "id": 4,
          "text": "Deficiency of fat soluble vitamins"
        },
        {
          "id": 5,
          "text": "Delirium"
        }
      ],
      "correct_choice_id": 2,
      "solution": "This patient with dyslipidemia is prescribed <strong>niacin</strong>, a lipid lowering drug, which causes an increase in <strong>blood uric acid</strong> levels and can <strong>induce gout</strong> (by inhibiting uric acid excretion and/or metabolism).<br><br>Normally, <strong>free fatty acids (FFA)</strong> are released by the action of <strong>hormone-sensitive lipase (HSL)</strong> on adipose tissue. This FFA is taken up by the liver to form <strong>triglycerides (TG)</strong>, which are one of the components of <strong>LDL and VLDL</strong>. <strong>Niacin&#160;</strong>prevents lipolysis by <strong>inhibiting HSL</strong> in adipose tissue which leads to a <strong>moderate decrease in VLDL and LDL levels</strong>. It can also cause a <strong>moderate increase in HDL</strong> by decreasing its uptake by the liver.<br><br><strong>Niacin&#160;</strong>can sometimes be indicated in the following circumstances: <br>&#160;<ul><li>&#160;To <strong>reduce LDL</strong> levels, uncontrolled by a combination of statins and ezetimibe&#160;</li><li>&#160;To <strong>elevate HDL levels</strong>&#160;</li><li>&#160;As an adjunct therapy for <strong>severe hypertriglyceridemia</strong>&#160;</li><li>&#160;To reduce the risk of recurrent myocardial infarction&#160;</li><li>&#160;In combination with bile acid resins to slow the progression of atherosclerotic cardiovascular &#160;disease (does not improve cardiovascular mortality or morbidity)&#160;</li></ul>Its use, however, is limited by its side effect profile, which include <strong>prostaglandin-induced facial flushing and pruritus</strong>, reversible <strong>increase in liver aminotransferases</strong>, postural hypotension, gastrointestinal upset, <strong>elevations in serum uric acid levels and increase in glucose levels</strong>. When used in combination <strong>with statins</strong>, it increases the risk of developing <strong>myopathy</strong>. &#160;<br><hr><h4 style='color: var(--accent-blue); margin-top:16px; margin-bottom:8px;'>Option Analysis</h4><div style='margin-bottom: 12px;'><strong>❌ Myopathy:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Myopathy is a potential adverse effect of statin therapy which decreases liver cholesterol production by inhibiting hydroxymethylglutaryl (HMG) CoA reductase. This patient is most likely prescribed niacin, which can cause myopathy but only when used in combination with a statin. &#160;</span></div><div style='margin-bottom: 12px;'><strong>✅ Hyperuricemia:</strong><br><span style='opacity:0.9'><strong>Correct</strong>: See Main Explanation. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Gallstones:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Gallstone formation is a potential side effect of fibrate therapy which inhibits cholesterol 7&#593; hydroxylase, an enzyme that synthesizes bile acids. This results in supersaturation of cholesterol in gallbladder and the formation of gallstones. It does not inhibit hormone-sensitive lipase in adipose tissue. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Deficiency of fat soluble vitamins:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Use of bile acid resins can lead to a deficiency of fat-soluble vitamins as it binds to bile acids (which help in the absorption of fat-soluble vitamins) in the intestine and prevent their reabsorption. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Delirium:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Delirium is an uncommon adverse effect of PCSK-9 inhibitors, which is a relatively new class of lipid-lowering drugs that act by inhibiting the degradation of LDL receptors, facilitating the removal of LDL from the bloodstream. No effect on lipolysis is observed. &#160;</span></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "N/A",
      "difficulty": "N/A"
    },
    {
      "text": "A 47-year-old man comes to the office because of muscle pain in his upper and lower extremities. He has been having a hard time raising his arms above his head for the past few days. The patient also reports that he easily gets fatigued and it is difficult for him to climb the stairs to his apartment. Past medical history is significant for hyperlipidemia. He was recently started on a low-fat diet and rosuvastatin to help reduce his blood cholesterol levels. Vitals are within normal limits. Physical examination shows weakness and soreness of proximal muscles of upper and lower extremities. Laboratory evaluation reveals elevated levels of serum creatine phosphokinase. Rosuvastatin is immediately discontinued and the patient is started on a new lipid lowering drug which interferes with the action of circulating proprotein convertase subtilisin/kexin type 9 (PCSK9). Which of the following best describes the function of PCSK9? &#160;",
      "choices": [
        {
          "id": 1,
          "text": "Conversion of hydroxymethylglutaryl (HMG) CoA to mevalonate"
        },
        {
          "id": 2,
          "text": "Degradation of low-density lipoprotein receptors (LDL-R) on liver cells"
        },
        {
          "id": 3,
          "text": "Hydrolysis of extracellular triglycerides in lipoprotein"
        },
        {
          "id": 4,
          "text": "Hydrolysis of intracellular of triglycerides in adipose tissue"
        },
        {
          "id": 5,
          "text": "Degradation of monoaminergic neurotransmitters"
        }
      ],
      "correct_choice_id": 2,
      "solution": "This patient is most likely suffering from <strong>statin-induced myopathy</strong> and is switched to a new and safer drug that inhibits the activity of PCSK9 (e.g., alirocumab, evolocumab).<br><br><strong>PCSK9</strong> is a serine protease, predominantly produced in the liver. It <strong>binds to the low-density lipoprotein receptors (LDL-R)</strong> on the surface of hepatocytes and leads to its degradation, thereby resulting in elevated blood cholesterol levels. <strong>PCSK9 inhibitors</strong> are <strong>antibodies that bind PCSK9</strong> and <strong>prevent LDL-R degradation</strong>. This leads to an overall increase in LDL-R on hepatocytes which results in a major <strong>decrease in serum LDL</strong> (by increasing its uptake in hepatocytes) and is indicated in patients with elevated LDL cholesterol. PCSK9 inhibitors are also shown to decrease the incidence of cardiovascular events in susceptible individuals. It is available as a subcutaneous injection and must be administered every 2-4 weeks. It is a comparatively safe lipid-lowering drug with occasional <strong>injection site reactions</strong> (pruritus, rash) and rare neurocognitive toxicity (delirium, dementia). Muscle toxicity, however, is not observed. &#160;<br><hr><h4 style='color: var(--accent-blue); margin-top:16px; margin-bottom:8px;'>Option Analysis</h4><div style='margin-bottom: 12px;'><strong>❌ Conversion of hydroxymethylglutaryl (HMG) CoA to mevalonate:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Hydroxymethylglutaryl (HMG) CoA reductase converts HMG CoA to mevalonate, which is a precursor of cholesterol. This enzyme is inhibited by statins and it results in decreased formation of cholesterol, thereby increasing the LDL receptors on hepatocytes and increasing the uptake of serum LDL. &#160;</span></div><div style='margin-bottom: 12px;'><strong>✅ Degradation of low-density lipoprotein receptors (LDL-R) on liver cells:</strong><br><span style='opacity:0.9'><strong>Correct</strong>: See Main Explanation. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Hydrolysis of extracellular triglycerides in lipoprotein:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Lipoprotein lipase (LPL) hydrolyzes extracellular triglycerides in lipoproteins to free fatty acids and monoglycerides. LPL activity is up-regulated via the activation of peroxisome proliferator-activated receptor alpha (PPAR&#945;) by fibrates. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Hydrolysis of intracellular of triglycerides in adipose tissue:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Hormone-sensitive lipase hydrolyzes intracellular triglycerides in adipose tissue to free fatty acids. It is stimulated by catecholamines, ACTH, and glucagon and inhibited by niacin (vitamin B3) which is sometimes indicated in the management of dyslipidemia. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Degradation of monoaminergic neurotransmitters:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Monoamine oxidase is responsible for the degradation of monoaminergic neurotransmitters (catecholamine, dopamine and serotonin) in the synaptic cleft. Monoamine oxidase inhibitors prevent the degradation of monoamines and are used in the treatment of major depressive disorder. It does not affect the serum lipid levels. &#160;</span></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "N/A",
      "difficulty": "N/A"
    },
    {
      "text": "A 46-year-old woman comes to the office for routine follow-up and has no active complaints at this visit. She was recently diagnosed with hypertriglyceridemia and was started on a low-fat diet along with fenofibrate. Past medical history is significant for hypertension. Current medications include fenofibrate and lisinopril. Family history is significant for myocardial infarction in her father. She does not use tobacco, alcohol or illicit drugs. Temperature is 37.0&#176;C (98.6&#176;F), pulse is 70/min, respirations are 16/min, and blood pressure is 130/85 mmHg. Physical examination is unremarkable. Repeat lipid panel revealed a triglyceride level of 900 mg/dL which was 1100 mg/dL a few weeks ago. A new supplement is added to her diet which decreases triglyceride levels by reducing the production of hepatic very low-density lipoprotein (VLDL) cholesterol. Which of the following nutrients is present in these supplements? &#160;",
      "choices": [
        {
          "id": 1,
          "text": "Niacin"
        },
        {
          "id": 2,
          "text": "Omega 3 fatty acids"
        },
        {
          "id": 3,
          "text": "Retinoic acid"
        },
        {
          "id": 4,
          "text": "Folate"
        },
        {
          "id": 5,
          "text": "Ascorbic acid"
        }
      ],
      "correct_choice_id": 2,
      "solution": "This patient with hypertriglyceridemia is prescribed an omega-3 fatty acid supplementation which reduces serum triglyceride (TG) levels. <strong>Eicosapentaenoic acid and docosahexaenoic acid are two common omega-3 fatty acids&#160;</strong>which <strong>decrease both fasting and postprandial TGs&#160;</strong>by <strong>reducing the hepatic VLDL production</strong>. The exact mechanism is not known but a number of theories had been proposed, which include: <br>&#160;<ul><li>&#160;Blockade of the enzyme responsible for TG synthesis in the liver (diacylglycerol acyltransferase or &#160; &#160;phosphatidic acid phosphohydrolase)&#160;</li><li>&#160;Increased plasma lipoprotein lipase activity&#160;</li><li>&#160;Decreased lipogenesis in the liver&#160;</li><li>&#160;Increase &#946; oxidation of fatty acids&#160;</li></ul>It is typically indicated in patients with <strong>hypertriglyceridemia (TG &gt; 150 mg/dL)</strong>. It also helps with improving blood pressure and cardiac function. Common adverse effects include <strong>gastrointestinal (GI) upset, fish-like taste</strong> and a possible increase in low-density lipoprotein (LDL). &#160;<br><hr><h4 style='color: var(--accent-blue); margin-top:16px; margin-bottom:8px;'>Option Analysis</h4><div style='margin-bottom: 12px;'><strong>❌ Niacin:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Niacin (vitamin B3) is used as a lipid lowering agent that acts by inhibiting hormone sensitive lipase in the adipose tissue, thereby preventing the mobilization of triglycerides. Although it reduces hepatic VLDL synthesis, its major role is to increase high-density lipoprotein (HDL) and is not used primarily in hypertriglyceridemia. &#160;</span></div><div style='margin-bottom: 12px;'><strong>✅ Omega 3 fatty acids:</strong><br><span style='opacity:0.9'><strong>Correct</strong>: See Main Explanation. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Retinoic acid:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Retinoic acid also known as vitamin A, is an antioxidant and is used primarily in the treatment of acute promyelocytic leukemia and severe acne as all-trans retinoic acid and isotretinoin, respectively. It has no known effect on triglyceride levels. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Folate:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Folate (vitamin B9) plays an important role in the synthesis of nitrogenous bases in DNA and RNA. Its supplementation is helpful in pregnant women and patients with megaloblastic anemia. No effect on lipid metabolism is observed. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Ascorbic acid:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Ascorbic acid (vitamin C) is an antioxidant that facilitates iron absorption in the intestine by reducing it to Fe<sup>+2</sup>. No effect on lipid metabolism is seen. &#160;</span></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "N/A",
      "difficulty": "N/A"
    },
    {
      "text": "A 45-year-old man comes to the office for routine follow-up. He was diagnosed with dyslipidemia 6 months ago on a fasting lipid panel. He has no active complaints at this visit. Past medical history is significant for hypertension and hypercholesterolemia. Current medications include lisinopril and atorvastatin. Family history is noncontributory. He smokes 1 pack of cigarettes daily, drinks 2-3 beers on weekends and does not use recreational drugs. Temperature is 37.0&#176;C (98.6&#176;F), pulse is 70/min, respirations are 16/min, and blood pressure is 130/85 mmHg. His BMI is 32.5 kg/m<sup>2</sup>. Physical examination is unremarkable. A repeat fasting lipid panel was obtained during today&#8217;s visit. Comparison of the results is shown below. The physician counseled him about dietary modifications and decided to add another lipid-lowering drug to this patient&#8217;s medication regimen which inhibits bile acid reabsorption in the intestine. Which of the following is the most likely medication this patient was started on? &#160;<br><br><table><tbody><tr><td><strong>Laboratory value</strong><br></td><td><strong>6 months ago</strong><br></td><td><strong>Today</strong><br></td></tr><tr><td>Total cholesterol<br></td><td>370 mg/dL<br></td><td>301 mg/dL<br></td></tr><tr><td>Low-density lipoprotein (LDL) &#160; <br></td><td>250 mg/dL<br></td><td>175 mg/dL<br></td></tr><tr><td>High-density lipoprotein (HDL) &#160; <br></td><td>30 mg/dL<br></td><td>33 mg/dL<br></td></tr><tr><td>Triglycerides (TGs) &#160; <br></td><td>90 mg/dL<br></td><td>89 mg/dL<br></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br>",
      "choices": [
        {
          "id": 1,
          "text": "Niacin"
        },
        {
          "id": 2,
          "text": "Cholestyramine"
        },
        {
          "id": 3,
          "text": "Fenofibrate"
        },
        {
          "id": 4,
          "text": "Ezetimibe"
        },
        {
          "id": 5,
          "text": "Alirocumab"
        }
      ],
      "correct_choice_id": 2,
      "solution": "This patient has <strong>hypercholesterolemia </strong>which is not significantly improving with mono-therapy with statins (atorvastatin). The new drug added to his regime is a <strong>bile acid resin</strong>, common examples of which include <strong>cholestyramine, colestipol </strong>and <strong>colesevelam</strong>.<br><br><strong>Bile acid resins</strong> are large, positively-charged molecules that bind to the negatively-charged bile acid in the intestine, <strong>inhibiting reabsorption at the intestinal brush border</strong>. The <strong>liver </strong>compensates for the decreased bile acids by <strong>increasing the production of bile salts</strong> via its <strong>up-regulation of LDL receptor</strong> and an <strong>increase in the synthesis of hydroxymethylglutaryl (HMG) CoA reductase</strong> (which converts HMG CoA to mevalonate, a cholesterol precursor). Bile acid resins are not as effective as statins, which increase the LDL receptors and inhibit HMG-CoA, and that is why they are usually used in combination with statins. The LDL receptors also very slightly increase the uptake of VLDL. A minor increase in HDL levels is also observed. Its combination with a non-statin lipid-lowering agent (e.g., niacin, fibrates) may be useful in patients who are statin-intolerant and require intensive lipid-lowering therapy. Common <strong>adverse effects</strong> associated with bile acid resins include <strong>gastrointestinal upset</strong> (nausea, bloating and cramping) and <strong>impaired absorption of fat-soluble vitamins (A, D, E and K) and drugs (e.g., digoxin, warfarin)</strong>. &#160;<br><hr><h4 style='color: var(--accent-blue); margin-top:16px; margin-bottom:8px;'>Option Analysis</h4><div style='margin-bottom: 12px;'><strong>❌ Niacin:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: &#160;Niacin, a lipid lowering drug, acts to prevent lipolysis by inhibiting hormone-sensitive lipase in adipose tissue. Its overall effect is a major increase in HDL and a decrease in LDL. It, however, does not affect intestinal absorption of bile acids. &#160;</span></div><div style='margin-bottom: 12px;'><strong>✅ Cholestyramine:</strong><br><span style='opacity:0.9'><strong>Correct</strong>: See Main Explanation. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Fenofibrate:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: This drug is a fibrate that activates PPAR-&#945;, causing the up-regulation of lipoprotein lipase levels to increase the clearance of serum triglycerides. This class of drugs also decreases very-low-density lipoproteins (VLDL) and induces HDL synthesis. It has no effect on bile acid reabsorption. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Ezetimibe:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Ezetimibe inhibits cholesterol (not bile acid) absorption at the intestinal brush border, reducing liver cholesterol stores and decreasing biliary bile content. &#160;</span></div><div style='margin-bottom: 12px;'><strong>❌ Alirocumab:</strong><br><span style='opacity:0.9'><strong>Incorrect</strong>: Alirocumab is a PCSK9 inhibitor that acts by inhibiting the degradation of LDL-R, facilitating the removal of LDL from the bloodstream. No effect on intestinal bile acid absorption is observed with the use of this drug. &#160;</span></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "N/A",
      "difficulty": "N/A"
    }
  ]
}